アブストラクト
Japanese
| Title | "パーキンソン病精神病 (Parkinson's Disease Psychosis)" とはなにか |
|---|---|
| Subtitle | 総説 |
| Authors | 三好功峰 |
| Authors (kana) | |
| Organization | 一般財団法人仁明会 精神衛生研究所 |
| Journal | 仁明会精神医学研究 |
| Volume | 17 |
| Number | 2 |
| Page | 37-46 |
| Year/Month | 2020 / 3 |
| Article | 報告 |
| Publisher | 仁明会 |
| Abstract | 「I. はじめに」パーキンソン病において精神病症状がみられることは稀ではない. L-ドパ治療によって出現する幻視, パーキンソン病認知症やレビー小体型認, 知症でみられる幻視, その他の幻覚, 妄想, 妄想性誤認症候群などは, パーキンソン病に関連してみられる精神病症状である. 近年, 米国において選択的セロトニン逆作動薬selective serotonin inverse agonistによって運動症状を悪化させることなく精神病症状を改善する治療が試みられるようになって, あらためて, パーキンソン病における精神病症状が注目されるようになった. このような「精神病症状を伴うパーキンソン病」は, しばしば "パーキンソン病精神病" と呼ばれている. そのような精神病症状の原因として, 大脳皮質のセロトニン系の過活性が想定されている. 本稿では, パーキンソン病精神病と呼ばれる状態について考察し, その原因として近年注目されているセロトニン-ドパミン不均衡仮説 (Stahl) について解説を加えることとしたい. |
| Practice | 臨床医学：一般 |
| Keywords | パーキンソン病精神病, 幻覚, 妄想, 気配感覚, セロトニン-ドパミン不均衡, Parkinson's Disease Psychosis, Hallucination, Delusion, Feeling of presence, serotonin-dopamine imbalance |
English
| Title | What is "Parkinson's Disease Psychosis"? |
|---|---|
| Subtitle | Review Article |
| Authors | Koho MIYOSHI |
| Authors (kana) | |
| Organization | Jinmeikai Research Institute for Mental Health |
| Journal | Jinmeikai Journal of Psychiatry |
| Volume | 17 |
| Number | 2 |
| Page | 37-46 |
| Year/Month | 2020 / 3 |
| Article | Report |
| Publisher | Jinmeikai |
| Abstract | [Abstract] "Parkinson's Disease Psychosis (PDP) is a clinical entity of Parkinson's disease (PD) with psychotic symptoms, including illusion, hallucination, feeling of presence, delusion and delusional misidentification. Similar psychotic symptoms may occur in association with Dementia with Lewy Bodies (DLB), or L-dopa induced psychosis in PD. Derangements of neurotransmitters, especially serotonin and dopamine, in cerebrum may cause PDP. Almost all anti-psychotic drugs are not recommended for the treatment of PDP, except clozapine and quetiapine. In US, pimavanserin, a potent antagonist at 5HT2A receptors without any D2 dopamine antagonist properties, is used recently for the treatment of PDP. Concept of PDP is reviewed in the present paper with brief comment of serotonin-dopamine imbalance hypothesis. |
| Practice | Clinical medicine |
| Keywords | Parkinson's Disease Psychosis, Hallucination, Delusion, Feeling of presence, serotonin-dopamine imbalance |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition(DSM-5). American Psychiatric Association 2013
- 2) Apaydin H, Benbir G : Capgras syndrome. During the course of Parkinson disease Dementia. J Neuropsychiat Clin Neurosci 26, e40, 2014
- 3) Ballanger B, Strafella AP, van Eimeren T, et al.: Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 67, 416-421, 2000
- 4) Berg D, Postuma RB, Bloem B, et al.: Time to redifine PD? Introductory statement of Parkinson's disease. Mov Disord 29, 454-462, 2014
- 5) Black KJ : Treatment of Parkinson's disease psychosis. Med Int Rev 27, 266-271, 2017
残りの57件を表示する
- 6) Chang A, Fox SH : Psychosis in Parkinson's disease : Epidemiology, pathophysiology, and management. Drugs 76, 1093-1118, 2016
- 7) Chaudhuri KR, Healy D, Schapira AHV, et al.: "The non motor symptoms of Parkinson's disease NMS Quest. Diagnosis and management". Lancet Neurol 5, 235-245, 2006
- 8) Chaudhuri KR, Martinez-Martin P, Brown RG, et al.: The metric properties of a novel non-motor symptoms scale for Parkinson's disease. Results from an International Pilot Study. Mov Disord 22, 1901-1911, 2007
- 9) Chaudhuri KR, Schapira AH : Non-motor symptoms of Parkinson's disease. dopaminergic pathophysiology and treatment. Lancet Neurol 8, 464-474, 2009
- 10) Chen JJ : Treatment of psychotic symptoms in patients with Parkinson disease. Mental Health Clin(Internet)7, 262-270, 2017
- 11) Combs BL, Cox AG : Update on the treatment of Parkinson's disease psychosis. Role of pimavanserin. Neurospcyhiatr Dis. Treat 13, 737-744, 2017
- 12) de Ajuriaguerra J : Etude psychopathologique des parkinsoniens. In : de Ajuriaguerra J, Gauthier G, editors. Monoamines, noyaux gris centraux et syndrome de Parkinson. Geneve. Masson. p327-55, 1971
- 13) Desmarais P, Massoud F, Filion J, et al.: Quetiapine for psychosis in Parkinson disease and neurodegenerative parkinsonian disorders : a systematic review. J Geriatr Psychiatry Neurol 29(4), 227-236, 2016
- 14) Fenelon G, Soulas T, Zenasni F, et al.: The changing face of Parkinson's disease-associated psychosis. A cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord 25, 755-759, 2010
- 15) Fernandez HH, Aarsland D, Fenelon G, et al.: Scales to assess psychosis in Parkinson's disease. Critique and recommendations. Mov Disord 23, 484-500, 2008
- 16) Ffytche DH, Aarsland D : Psychosis in Parkinson's disease. Int Rev Neurobiol, 133, 585-622, 2017
- 17) Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease : on movement, mood and madness. Mov Disord 24, 1255-1266, 2009
- 18) Francis PT, Perry EK : Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov Disord 22, suppl 17, S251-357, 2007
- 19) Friedman JH : Parkinson's disease psychosis. Update. Behaviour Neurol 27, 469-477, 2013
- 20) Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother 12, 2009-2024, 2011
- 21) Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson's Disease. Curr Treat Options Neurol 16, 281, 2014
- 22) Huot P, Hohnston TH, Darr T, et al.: Increased 5HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 25, 1399-1408, 2010
- 23) Huot P, Fox SH. The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp Brain Res. 230, 463-476, 2013
- 24) Jakel R, Stacy M : Parkinson's disease psychosis. Neuropsychiatric Dis Treat 4, 41-51, 2014
- 25) Klein JC, Eggers C, Kalbe E, et al.: Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 74, 885-892, 2010
- 26) Kometer M, Schmidt A, Jancke L, et al.: Activations of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci 33, 10544-10551, 2013
- 27) Lee AH, Weintraub D : Psychosis in Parkinson's disease without dementia. Common and comorbid with other non-motor symptoms. Mov Disord 27, 858-863, 2012
- 28) Lenka A, Pagonabarraga J, Pal PK, et al.: Minor hallucinations in Parkinson disease. A subtle symptom with minor clinical implications. Neurology 93, 259-266, 2019
- 29) Lippa CF, Duda JE, Crossman M, et al.: DLB and PDD boundary issues. Diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68, 812-819, 2007
- 30) Mahlknecht P, Seppi K, Poewe W : The concept of prodromal Parkinson's disease. J Parkinson's Dis. 5, 681-697, 2015
- 31) McKeith IG, Galasko D, Kosaka K, et al.: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies(DLB). Report of the consortium on DLB international workshop. Neurology 47, 1113-1124, 1996
- 32) McKeith IG, Dickson DW, Lowe J, et al.: Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 65, 1863-1872, 2005
- 33) McKeith IG, Boeve BF, Dickson DW, et al.: Diagnosis and management of dementia with Lewy bodies. Fourth consensus report of the DLB Consortium. Neurology 89, 88-100, 2017
- 34) Meltzer HY, Mills R, Revell, et al.: Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacol. 35, 881-892, 2010
- 35) Miyasaki JM, Shannon K, Voon V, et al.: Practice parameter. Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease(an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66, 996-1002, 2006
- 36) Miyoshi K, Ueki A, Nagano O : Management of psychiatric symptoms of Parkinson's disease. Eur Neurol 36(suppl.), 49-54, 1996
- 37) 三好功峰 : レビー小体病の幻視について-症状, 機序, 治療. 仁明会精神医学研究 14, 13-28, 2017
- 38) 三好功峰 : レビー小体病の妄想性誤認症候群について. 仁明会精神医学研究 15, 13-25, 2018
- 39) 三好功峰 : パーキンソン病とレビー小体病神経精神医学の立場から. 仁明会精神医学研究 16, 35-42, 2019
- 40) 三好功峰 : パーキンソン病におけるfeeling of presence(気配感覚)について. 仁明会精神医学研究 17, 36-43, 2019
- 41) 永野 修, 守田嘉男, 西谷 裕ほか : パーキンソン病治療中にみられる幻覚症状について. 臨床神経学 26, 464-469, 1986
- 42) Ohno Y, Shimizu S, Tokudome K, et al.: New insight into the therapeutic role of the serotonergic system in Parkinson's disease. Prog Neurobiol 134, 104-121, 2015
- 43) Ondo WG, Sarfaraz S, Lee M : A novel scale to assess psychosis in patients with Parkinson's disease. J Clin Mov Disord 2, 17, 2015
- 44) Pagonabarraga J, Soriano-Mas C, Llebaria G, et al.: Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 20, 290-296, 2014
- 45) Pagonabarraga J, Martinez-Horta S, Fernandez de Bobadilla R, et al.: Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov Disord 31, 45-52, 2016
- 46) Perry EK, Perry RH : Acetylcholine and hallucination. Disease related compared to drug-induced alterations in human consciousness. Brain Cogn 28, 240-258, 1995
- 47) Politis M, Niccolini F. Serotonin in Parkinson's disease. Behav Brain Res 277, 136-145, 2015
- 48) Postuma RB, Berg D, Stem M, et al.: Abolishing the 1-year rule. How much evidence will be enough? Mov Disord 31, 1623-1627, 2016
- 49) Ravina B, Marder K, Fernandez HH, et al.: Diagnostic criteria for psychosis in Parkinson's disease. report of an NINDS, NIMH work group. Mov Disord 22, 1061-1068, 2007
- 50) Rondot P, de Recondo J, Coignet A, et al.: Mental disorders in Parkinson's disease after treatment with L-DOPA. Adv Neurol 40, 259-269, 1984
- 51) Sellers J, Darby R, Classsen D : Clinical experience with pimavanserin for treatment of Parkinson's disease psychosis. Neurology 90(15 suppl.), 2018
- 52) Seppi K, Weintraub D, Coelho M, et al : The Movement Disorder Society evidence-based medicine review update. Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 26, 42-80, 2011
- 53) Seppi K, Chaudhuri KR, Coelho M, et al.: Update on treatments for monmotor symptoms of Parkinson's disease. An evidence-based medicine review. Mov Disord 34, 180-198, 2019
- 54) Shimada H, Hirano S, Shintoh H, et al.: Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73, 273-278, 2009
- 55) Spiegel D, Larola R, Samuels D : A possible case of Capgras syndrome after a right anterior cerebral artery cerebrovascular accident treated successfully with mirtzalpine. J Neuropsychiat Clin Neurosci 20, 494, 2008
- 56) Stahl SM : Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectrum 21, 355-359, 2016
- 57) Taddei RN, Cankaya S, Dhaliwal S, et al.: Management of psychosis in Parkinson's disease. Emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Parkinson's Dis. 2017 ; 2017 : 3256542. doi : 10.1155/2017/3256542
- 58) Tampi RR, Tampi DJ. Young JJ, et al.: Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. World J Psychiatr 9, 47-54, 2019
- 59) Thanvi BR, Lo TCN, Harsh DP : Psychosis in Parkinson's disease. Postgrad Med J, 81, 644-646, 2005
- 60) Tiraboschi P, Hansen LA, Alford M, et al.: Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer's disease. Arch Gen Psychiat 59, 946-951, 2002
- 61) World Health Organization : International Classification of Diseases 11th Revision. (ICD-11). World Health Organization 2018
- 62) Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease : a review. Drugs Aging 25, 665-682, 2008
